Tacrolimus Associated Tremors in Liver Transplantation: Immediate-Release Versus Extended-Release Formulations

• Status: Not yet recruiting
• Trial end date: 2024-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a randomized open label study in de novo liver transplant recipients that aims to compare the risk of tacrolimus induced tremors with once daily extended-release formulation, Envarsus, versus the twice daily immediate-release formulation. Both formulations of tacrolimus are currently approved for the prevention of rejection in liver transplant patients.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of British Columbia
• Collaborator: Paladin Labs Inc.
• Treatments: Tacrolimus

Criteria

Inclusion Criteria:

1. Adults aged 18 years or older

2. Recipients of a first-time liver transplant

3. eGFR more than 30 ml/min on the day of tacrolimus initiation

4. All patients who are eligible to initiate Tacrolimus within 7 days post-liver transplant

5. Informed consent

Exclusion Criteria:

1. Recipients of prior organ transplant

2. Need for hemodialysis either prior or following liver transplantation

3. Recipients of living donor liver or split deceased donor liver allografts

4. Recipients of combined liver/kidney transplants

5. Recipients receiving liver allografts from donors with HCV viremia (detected through nucleic acid testing or other means)

6. Patients with a history of tremor prior to transplantation including essential tremors, Parkinson's or Parkinsonian syndromes

7. Patients receiving concomitant medications known to induce tremors such as dopamine blocking agents

8. Baseline TSH, T3, T4 indicating hyperthyroidism